Gaithersburg, MD, November 5, 2024 -- Remedy Plan Therapeutics (“Remedy Plan”), a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, announced today that preclinical data will be presented from its clinical candidate, RPT1G, at the 66th American Society of Hematology Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, CA.

Title: The Hyperbolic NAMPT Inhibitor RPT1G Synergizes with BCL-2 Family Inhibitors and Helps Overcome Venetoclax Resistance in Acute Myeloid Leukemia Cells.

Authors: Gregory Crimmins, Min Wu, Francis Roushar, Claudia F. Ramos Aguilar, Mehdi Gharghabi, Banumathi Cole, Rosa Lapalombella and Dennise A. De Jesús-Díaz

Full Abstract: The Hyperbolic NAMPT Inhibitor RPT1G Synergizes with BCL-2 Family Inhibitors and Helps Overcome Venetoclax Resistance in Acute Myeloid Leukemia Cells

Session Name: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III

Session Date and Time: December 9, 2024, 6:00 - 8:00 PM PT

Location: San Diego Convention Center, Halls G-H

Poster #: 4134

About RPT1G

RPT1G is a small molecule NAMPT inhibitor that is thousands-fold better tolerated by healthy cells than other NAMPT inhibitors and avoids the severe on-target toxicities reported for other NAMPT inhibitors. RPT1G achieves this differentiation through a first-in-class, hyperbolic mechanism of inhibition that is optimized to preserve cellular metabolism in healthy cells, while inhibiting activity in malignant cells.

About Remedy Plan Therapeutics

Remedy Plan is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for allosteric inhibition of NAMPT that is fractional and highly tunable. NAMPT is an enzyme that controls how cells use energy and is core to human biology and its dysregulation is responsible for over 20 diseases. Efforts to reduce NAMPT activity to date have resulted in unmanageable toxicities to healthy cells due to the essential role of NAMPT in healthy cell functioning and disease. Remedy Plan’s groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. Remedy Plan's novel mechanism of NAMPT inhibition can address hematological malignancies, metabolic, and autoimmune diseases. Learn more about Remedy Plan at remedyplan.com.

Contact: Parisa Moghaddam-Taaheri ([email protected])